Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
The purpose of this registry is to collect data that describes the characteristics of people with advanced cancer for whom the Guardant360 assay is ordered and to observe their clinical outcomes after receiving their results.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 10, 2019 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Guardant Health, Inc.
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
General 1. 18 Years of age or older 2. Ability to provide written informed consent 3. Blood collected for the most recent Guardant360 test within 8 weeks prior to enrollment General
- 1. Pregnancy at the time of the qualifying Guardant360 blood collection 2. History of the allogeneic organ or tissue transplant Module 1 (Non-Small Cell Lung Cancer) Inclusion Criteria 1. NSCLC, confirmed by histology or cytology 2. Advanced disease, defined as: stage IIIB or IV NSCLC at the time of the qualifying Guardant360 blood collection; or for subjects with an initial diagnosis of Stage I-IIIA disease, NSCLC that is recurrent or metastatic at the time of the qualifying Guardant360 blood collection 3. One of the following conditions at the time of the qualifying Guardant360 blood collection:
- No prior systemic therapy for advanced disease OR
- All three of the following conditions: 1\. A history of prior systemic therapy for advanced disease, 2. Disease progression within the previous four weeks, \& 3. No new systemic therapy for advanced disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Holy CrossFort Lauderdale, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 10, 2019. Always confirm current availability with the study team.